Relutrigine

The disease burden includes early-onset seizures, developmental impairment, and substantial treatment exposure. In a SCN2A-related disorder cohort, developmental delay or intellectual disability was present in 91 of 100 participants. In a SCN8A caregiver survey, 77% were taking at least two antiseizure medications and 50% had previously tried and stopped at least four. A separate SCN8A mortality study reported 5.3% mortality among 190 participants. These estimates come from different populations and should not be treated as a single cohort.

EMBOLD randomized 16 participants in cohort 1 and 53 in cohort 2. Reported placebo-adjusted motor seizure reductions over 16 weeks were 46% in cohort 1 and 53% in the confirmatory cohort. Cohort 1 adverse events included infections, vomiting, pyrexia, somnolence, and constipation. The healthy-volunteer PRAX-562-102 combination study is a separate safety dataset: one participant experienced three study-drug-related serious adverse events, and Part B stopped early.

The available economic material is a U.S. sales forecast, ranging from $5 million in 2026 to $685 million in 2030. These figures describe projected sales, not a payer budget-impact model or annual treatment cost per participant.

The randomized EMBOLD evidence supports reduced motor seizure frequency in the studied SCN2A- and SCN8A-DEE populations. Longer-term seizure reduction is reported from an open-label extension involving 13 participants, which lacks a concurrent placebo comparison. Relutrigine remains investigational; the updated FDA target action date is December 27, 2026. Reported seizure outcomes do not, by themselves, establish improvement in health-related quality of life.